Molecular therapeutic strategies in hepatitis B virus infection.
Chronic infection with the hepatitis B virus is a major health problem worldwide. The only established therapy is interferon-alpha, with an efficacy of only 30-40% in highly selected patients. Nucleoside analogues do not show a significant clinical benefit. Molecular therapeutic strategies aimed at blocking gene expression include antisense DNA/RNA and ribozymes acting at the posttranscriptional level and triple helix formation blocking at the transcriptional level. In vitro, antisense oligodeoxynucleotides inhibit viral replication and gene expression in human hepatoma cell lines. In vivo, an antisense oligodeoxynucleotide directed against the 5'-region of the pre-S gene of the duck hepatitis B virus inhibited viral replication and gene expression in ducks. In vitro, ribozymes accurately cleave HBV substrate RNA. Triple helix formation is another very promising molecular approach. Results in hepadnaviral infection are not yet available, however.
Offensperger
W B
WB
Medizinische Universitätsklinik, Freiburg, Germany.
Blum
H E
HE
Gerok
W
W
D001483:Base Sequence; D016373:DNA, Antisense / Q000627:therapeutic use*; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D006509:Hepatitis B / Q000628:therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D016372:RNA, Antisense / Q000627:therapeutic use*; D016337:RNA, Catalytic / Q000627:therapeutic use*; D014158:Transcription, Genetic / Q000187:drug effects
D016373:DNA, Antisense; D004279:DNA, Viral; D016372:RNA, Antisense; D016337:RNA, Catalytic